ahlam1399
03-15-2016, 01:17 PM
FDA to review Roche?s bladder cancer drug on priority basis
ZURICH (Reuters) - The U.S. Food and Drug Administration has granted a priority review status to Roche's immu**therapy to treat advanced bladder cancer, the Swiss pharmaceutical maker said on Tuesday.
http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/1/rc.img (http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/1/rc.htm)
http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/2/rc.img (http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/2/rc.htm)
http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/3/rc.img (http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/3/rc.htm)
http://da.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/a2.img (http://da.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/a2.htm)
http://adchoice.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/ach.img (http://adchoice.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/ach.htm)http://pi.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/a2t.imghttp://pi2.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e444a6e/sc/19/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=W-1whygubIY:MDE89Wi4R0w:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=W-1whygubIY:MDE89Wi4R0w:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=W-1whygubIY:MDE89Wi4R0w:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=W-1whygubIY:MDE89Wi4R0w:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=W-1whygubIY:MDE89Wi4R0w:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/W-1whygubIY
ZURICH (Reuters) - The U.S. Food and Drug Administration has granted a priority review status to Roche's immu**therapy to treat advanced bladder cancer, the Swiss pharmaceutical maker said on Tuesday.
http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/1/rc.img (http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/1/rc.htm)
http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/2/rc.img (http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/2/rc.htm)
http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/3/rc.img (http://rc.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/rc/3/rc.htm)
http://da.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/a2.img (http://da.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/a2.htm)
http://adchoice.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/ach.img (http://adchoice.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/ach.htm)http://pi.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/a2t.imghttp://pi2.feedsportal.com/r/247394757675/u/49/f/654207/c/35217/s/4e444a6e/sc/19/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e444a6e/sc/19/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=W-1whygubIY:MDE89Wi4R0w:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=W-1whygubIY:MDE89Wi4R0w:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=W-1whygubIY:MDE89Wi4R0w:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=W-1whygubIY:MDE89Wi4R0w:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=W-1whygubIY:MDE89Wi4R0w:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/W-1whygubIY